Century Therapeutics, Inc.
NASDAQ:IPSCBiotechnology
+$0.01 today
- Market cap
- $250.60M
- Beta
- 1.57
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.25
Volume 1.14M
Average 1.12M
IPSC Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Century Therapeutics, Inc.NASDAQ: IPSC
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income turns negative
Q1 FY2026 operating income was -$25.5M, compared with $74.18M a year earlier. Trailing-twelve-month operating income was -$116.94M.
Context
- Operating income amounted to 13.8% of revenue in FY2025, down 2082.7 pp from a year earlier.
- Operating income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate from 4 analysts of -$44.23M (-194.1%) for the fiscal year ending Dec 2026, a slowdown from the +89.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$25.5M-23.5% QoQ
- Last fiscal yearDec 2025
- -$15.04M+89.1% YoY
- LTMMar 2026
- -$116.94M-258.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -134.4% | +34.5% | +168.9 pp |
| 1 year | +89.1% | -194.1% | -283.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (15.04M) USD
- Year-over-year change
- +89.1%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (15.04M) | +89.1% |
| FY2024 | 2024-12-31 | (138.14M) | +5.7% |
| FY2023 | 2023-12-31 | (146.55M) | -9.5% |
| FY2022 | 2022-12-31 | (133.83M) | -41.0% |
| FY2021 | 2021-12-31 | (94.88M) | — |
Operating Income vs competitors
How IPSC compares with its peers on the latest reported figures
- IPSC's LTM Mar 2026 operating income of -$116.94M is the lowest of the 8 companies compared; the peer median is -$20.38M.
- Its year-over-year change of -258.1% is the lowest of 8, against a peer median of +20.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$9.39M | +25.3% | — | — | |
| LTM Mar 2026 | -$12.9M | -15.3% | — | 912.4% | |
| LTM Mar 2026 | -$19.58M | +52.4% | — | 59.8% | |
| LTM Mar 2026 | -$20.38M | -42.0% | — | — | |
OSTXOS Therapies Incorporated | LTM Mar 2026 | -$33.87M | -202.9% | — | — |
| LTM Mar 2026 | -$60.57M | +20.8% | — | 18182.8% | |
| LTM Mar 2026 | -$84.21M | +29.2% | — | 55.7% | |
| LTM Mar 2026 | -$116.94M | -258.1% | — | — | |
| Peer median (excluding IPSC) | -$20.38M | +20.8% | — | 486.1% | |
Competitors are the stored peer set for IPSC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 5.2M | 2.24M | 6.59M | 109.16M |
| Cost of Revenue | 4.58M | 0 | 0 | 0 | 13.1M |
| Gross Profit | (4.58M) | 5.2M | 2.24M | 6.59M | 96.06M |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 88.0% |
| Research & Development | 75.65M | 97.17M | 92.71M | 107.24M | 95.67M |
| Selling, General & Admin | 14.65M | 31.86M | 34.71M | 33.16M | 24M |
| Operating Expenses | 90.3M | 139.03M | 148.78M | 144.73M | 111.1M |
| Depreciation & Amortization | 4.58M | 8.44M | 13.04M | 13.3M | 13.1M |
| EBITDA | (89.92M) | (121.2M) | (121.21M) | (111.47M) | 3.45M |
| EBITDA Margin | — | -2331.2% | -5423.2% | -1691.8% | 3.2% |
| Operating Income | (94.88M) | (133.83M) | (146.55M) | (138.14M) | (15.04M) |
| Operating Margin | — | -2574.2% | -6556.9% | -2096.5% | -13.8% |
| Interest Income | 898K | 2.99M | 12.68M | 13.01M | 7.35M |
| Interest Expense | 1.28M | 0 | 540K | 0 | 0 |
| Other Income / Expenses | (898K) | 2.99M | 11.75M | 13.36M | 5.39M |
| Income Before Tax | (95.78M) | (130.84M) | (134.79M) | (124.78M) | (9.65M) |
| Pre-Tax Margin | — | -2516.7% | -6031.0% | -1893.7% | -8.8% |
| Income Tax Expense | 43K | 91K | 1.88M | 1.79M | (68K) |
| Net Income | (95.82M) | (130.93M) | (136.67M) | (126.57M) | (9.58M) |
| Net Margin | — | -2518.4% | -6115.1% | -1920.9% | -8.8% |
| EPS (Basic) | (1.74) | (2.27) | (2.30) | (1.61) | (0.11) |
| EPS (Diluted) | (1.74) | (2.27) | (2.30) | (1.61) | (0.11) |
| Weighted Avg Shares | 55.01M | 57.76M | 59.31M | 78.65M | 86.56M |
| Weighted Avg Shares (Diluted) | 55.01M | 57.76M | 59.31M | 78.65M | 86.56M |
Century Therapeutics, Inc.
NASDAQ:IPSC
Intrinsic Alpha fair value
Locked
Current Price
$1.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.